Cerus Corporation (CERS) Shares Sold by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC reduced its position in shares of Cerus Corporation (NASDAQ:CERS) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,600 shares of the biotechnology company’s stock after selling 1,050 shares during the period. Janney Montgomery Scott LLC’s holdings in Cerus Corporation were worth $119,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Marathon Capital Management raised its stake in shares of Cerus Corporation by 32.4% in the first quarter. Marathon Capital Management now owns 24,500 shares of the biotechnology company’s stock worth $109,000 after buying an additional 6,000 shares during the last quarter. Budros Ruhlin & Roe Inc. raised its stake in shares of Cerus Corporation by 41.7% in the first quarter. Budros Ruhlin & Roe Inc. now owns 25,470 shares of the biotechnology company’s stock worth $113,000 after buying an additional 7,500 shares during the last quarter. Bellevue Group AG purchased a new stake in shares of Cerus Corporation during the first quarter worth about $134,000. Russell Investments Group Ltd. purchased a new stake in shares of Cerus Corporation during the first quarter worth about $137,000. Finally, American International Group Inc. raised its stake in shares of Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock worth $278,000 after buying an additional 4,127 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors.
Shares of Cerus Corporation (CERS) opened at 2.38 on Wednesday. The stock’s market cap is $259.75 million. Cerus Corporation has a 52-week low of $1.93 and a 52-week high of $7.19. The stock’s 50 day moving average price is $2.37 and its 200-day moving average price is $3.24.
Cerus Corporation (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. Cerus Corporation’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.18) EPS. On average, analysts predict that Cerus Corporation will post ($0.68) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Cerus Corporation (CERS) Shares Sold by Janney Montgomery Scott LLC” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/cerus-corporation-cers-shares-sold-by-janney-montgomery-scott-llc/1530766.html.
A number of brokerages have issued reports on CERS. Cantor Fitzgerald set a $9.00 target price on Cerus Corporation and gave the company a “buy” rating in a research report on Thursday, May 4th. Zacks Investment Research lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Friday, May 26th. BidaskClub raised Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. BTIG Research reissued a “buy” rating and issued a $5.00 target price on shares of Cerus Corporation in a research report on Sunday, May 28th. Finally, ValuEngine lowered Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.25.
In other news, insider Laurence M. Corash acquired 92,796 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average cost of $2.45 per share, with a total value of $227,350.20. Following the acquisition, the insider now owns 1,375,711 shares in the company, valued at $3,370,491.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.40% of the stock is currently owned by corporate insiders.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.